Opinion: Drug pricing legislation will kill Illinois’ startup bioscience industry – Crain’s*

CEO of the Illinois Biotechnology Innovation Organization, iBIO, in Chicago: Allowing the government to dictate what a company may charge for a novel drug will have a chilling effect on innovation. Economic studies on the impact of government price setting, including non-partisan reports by the Congressional Budget Office (CBO), have warned that “negotiations” will result in fewer new medications, essentially defunding R&D for the most challenging diseases. This could mean less money for new treatments for Alzheimer’s, cancer and rare diseases.

SIGN UP HERE FOR FREE WIREPOINTS DAILY NEWSLETTER

Home Page Signup
First
Last
Check what you would like to receive:

FOLLOW US

 

WIREPOINTS ORIGINAL STORIES

Mark Glennon on AM560’s Morning Answer: Chicago pension buyout plan mostly shifts debt rather than eliminating it, property tax surge doubles inflation over three decades

Chicago’s political leadership is floating a pension buyout program as evidence it is seriously addressing the city’s thirty-six-billion-dollar unfunded pension liability, but Mark Glennon, founder of the Illinois policy research organization Wirepoints, said that the proposal moves debt from one column to another rather than reducing it, and that the broader fiscal picture facing the city continues to deteriorate across every measurable dimension. Audio here.

Read More »

WE’RE A NONPROFIT AND YOUR CONTRIBUTIONS ARE DEDUCTIBLE.

SEARCH ALL HISTORY

CONTACT / TERMS OF USE